Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results

Overview

Journal Arch Drug Inf

Specialty Pharmacology

Date 2009 Aug 18

PMID 19684847

Citations 3

Authors

Serdar Guler

Surendra Kumar Sharma

Majeed Almustafa

Chong Hwa Kim

Sami Azar

Rucsandra Danciulescu

Marina Shestakova

Duma Khutsoane

Ole Molskov Bech

Affiliations

Soon will be listed here.

Abstract

AIMS: This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinediones (TZD) after failing oral antidiabetic drugs (OADs) treatment. METHODS: This was a multi-national, multi-centre, six-month, prospective, open-labelled, uncontrolled, clinical experience evaluation study, with the exception of a three-month study in one country (China) ("all exclude China" and "China"). Initiation and discontinuation of BIAsp 30 treatment were entirely at the discretion of the attending physicians. RESULTS: Mean HbA(1c), FPG and PPPG were significantly reduced from baseline at three and six months in all groups (P < 0.001). In "all exclude China", reductions in mean HbA(1c), FPG and PPPG at six months were as follows: BIAsp 30-only group (-2.12 +/- 1.76% points; -4.82 +/- 3.86 mmol/L; -6.89 +/- 4.74 mmol/L), BIAsp 30 + BI group (-2.24 +/- 1.77% points; -4.48 +/- 3.68 mmol/L; -6.66 +/- 4.55 mmol/L), BIAsp 30 + SU group (-1.95 +/- 1.59% points; -3.98 +/- 3.19 mmol/L; -6.25 +/- 4.45 mmol/L) and BIAsp 30 + SU + BI group (-1.78 +/- 1.20% points; -3.57 +/- 2.78 mmol/L; -5.89 +/- 3.98 mmol/L). The only serious adverse drug reaction was reported by the BIAsp 30-only group. In the "China" group, reductions in mean HbA(1c), FPG and PPPG at three months were: BIAsp 30-only group (-2.16 +/- 1.52% points; -3.34 +/- 2.49 mmol/L; -6.29 +/- 3.92 mmol/L), BIAsp 30 + BI group (-2.44 +/- 1.52% points; -4.01 +/- 2.50 mmol/L; -7.10 +/- 3.96 mmol/L), BIAsp 30 + GI group (-2.33 +/- 1.41% points; -4.34 +/- 2.52 mmol/L; -7.97 +/- 3.99 mmol/L) and BIAsp 30 + BI + TZD group (-1.21 +/- 1.60% points; -3.50 +/- 2.29 mmol/L; -5.97 +/- 3.39 mmol/L). No serious ADR were reported in China. The most frequent hypoglycaemic episodes were diurnal and minor in nature. CONCLUSIONS: BIAsp 30 treatment in a clinical setting improved glycaemic control in type 2 diabetes patients failing OADs.

Citing Articles

Czech M, Rdzanek E, Paweska J, Adamowicz-Sidor O, Niewada M, Jakubczyk M BMC Endocr Disord. 2015; 15:57.

PMID: 26458540 PMC: 4603823. DOI: 10.1186/s12902-015-0052-z.

Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.

Liebl A, Prusty V, Valensi P, Kawamori R, Christiansen J, Palmer A Drugs. 2012; 72(11):1495-520.

PMID: 22818015 PMC: 3590411. DOI: 10.2165/11635490-000000000-00000.

The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs.

Gu Y, Hou X, Zhang L, Pan J, Cai Q, Bao Y Diabetes Technol Ther. 2011; 14(3):244-50.

PMID: 22047050 PMC: 3284695. DOI: 10.1089/dia.2011.0168.

References

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Wright A, Burden A, Paisey R, Cull C, Holman R . Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002; 25(2):330-6. DOI: 10.2337/diacare.25.2.330. View

Jacobsen L, Sogaard B, Riis A . Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000; 56(5):399-403. DOI: 10.1007/s002280000159. View

Boehm B, Home P, Behrend C, Kamp N, Lindholm A . Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med. 2002; 19(5):393-9. DOI: 10.1046/j.1464-5491.2002.00733.x. View

Garber A . Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006; 66(1):31-49. DOI: 10.2165/00003495-200666010-00003. View

Goudswaard A, Furlong N, Rutten G, Stolk R, Valk G . Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004; (4):CD003418. PMC: 9007040. DOI: 10.1002/14651858.CD003418.pub2. View

Turner R, Cull C, Frighi V, Holman R . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21):2005-12. DOI: 10.1001/jama.281.21.2005. View

Leiter L, Ceriello A, Davidson J, Hanefeld M, Monnier L, Owens D . Postprandial glucose regulation: new data and new implications. Clin Ther. 2006; 27 Suppl B:S42-56. DOI: 10.1016/j.clinthera.2005.11.020. View

. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006; 23(6):579-93. DOI: 10.1111/j.1464-5491.2006.01918.x. View

10.

Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Harman-Boehm I . Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther. 2004; 25(12):3109-23. DOI: 10.1016/s0149-2918(03)90095-6. View

11.

Raskin P, Allen E, Hollander P, Lewin A, Gabbay R, Hu P . Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005; 28(2):260-5. DOI: 10.2337/diacare.28.2.260. View

12.

Nathan D, Roussell A, Godine J . Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Ann Intern Med. 1988; 108(3):334-40. DOI: 10.7326/0003-4819-108-3-334. View

13.

Bretzel R, Voigt K, Schatz H . The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106(5):369-72. View

14.

Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H . Implications of the United kingdom prospective diabetes study. Diabetes Care. 2002; 26 Suppl 1:S28-32. DOI: 10.2337/diacare.26.2007.s28. View

15.

Christiansen J, Vaz J, Metelko Z, Bogoev M, Dedov I . Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab. 2003; 5(6):446-54. DOI: 10.1046/j.1463-1326.2003.00300.x. View

16.

Khutsoane D, Sharma S, Almustafa M, Jang H, Azar S, Danciulescu R . Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008; 10(3):212-22. DOI: 10.1111/j.1463-1326.2007.00826.x. View

17.

Nathan D, Buse J, Davidson M, Heine R, Holman R, Sherwin R . Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29(8):1963-72. DOI: 10.2337/dc06-9912. View

18.

Kvapil M, Swatko A, Hilberg C, Shestakova M . Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab. 2005; 8(1):39-48. DOI: 10.1111/j.1463-1326.2005.00492.x. View

19.

Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P . Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003; 17(6):307-13. DOI: 10.1016/s1056-8727(03)00076-x. View

20.

Boehm B, Vaz J, Brondsted L, Home P . Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2005; 15(8):496-502. DOI: 10.1016/j.ejim.2004.10.001. View